Patients with colorectal cancer whose primary tumor is situated on the left side of the colon survive significantly longer than patients whose cancer starts on the right side, says new research to be presented at a meeting next month.
The study - the largest of its kind so far to look at tumor location in colorectal cancer - is a retrospective analysis of data from a large clinical trial designed to compare the effectiveness of two drugs for treating metastatic colorectal cancer.
The analysis shows that patients whose primary tumor is on the left of the colon (the side comprising the descending colon, sigmoid colon, and rectum) have a significantly longer survival than patients whose primary tumor is on the right side (where the cecum and ascending colon are located).
Lead author Alan P. Venook, a professor of medicine at the University of California-San Francisco (UCSF), explains that while previous studies have suggested tumor site can influence clinical outcomes in colorectal cancer, the effect they observed in their analysis is much bigger than they expected.
The study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, June 3-7, 2016.
ASCO President Julie M. Vose says this unexpected discovery "could answer some long-standing questions about why certain patients do better than others."
The data came from a clinical trial that compared bevacizumab and cetuximab in combination with chemotherapy as initial therapy for metastatic colorectal cancer.
Patients with left-sided primary tumors lived longer
In their main analysis, the researchers used data on 293 patients with right-sided primary tumors and 732 patients with left-sided primary tumors.
This analysis found that patients with left-sided primary tumors had a median overall survival of 33.3 months, compared with 19.4 months in patients with right-sided primary tumors.
Of the patients treated with cetuximab, those with left-sided primary tumors lived 36 months, while patients with right-sided primary tumors lived 16.7 months.
The analysis showed a similar pattern for patients treated with bevacizumab: 31.4 months overall survival for those with left-sided tumors and 24.2 months for those with right-sided tumors.
Another way to look at these results is from the point of view of tumor location first, then treatment. This shows if the tumor was on the right, patients receiving bevacizumab had a longer survival than patients receiving cetuximab (24.2 months and 16.7 months, respectively).
Conversely, patients with left-sided tumors treated with cetuximab lived 36 months, while those receiving bevacizumab lived 31.4 months.
As the clinical trial comparing the two drugs was under way, it was discovered that mutations in the KRAS gene is an important factor in the use of cetuximab.
When the researchers analyzed the data just for patients with KRAS mutations, they found a similar pattern to the previous results: patients with left-sided tumors lived longer compared with patients with right-sided tumors.
The researchers conclude that whether the primary tumor was on the left or the right likely influenced the effectiveness of the treatments the patients received in the trial.
They are now looking into the molecular biology mechanisms that might explain such differences.
"These findings will likely change the way we approach colorectal cancer treatment and research, even as we seek to more deeply understand the biology driving the difference in outcomes between right- and left-sided cancers."
Prof. Alan P. Venook
The study - the largest of its kind so far to look at tumor location in colorectal cancer - is a retrospective analysis of data from a large clinical trial designed to compare the effectiveness of two drugs for treating metastatic colorectal cancer.
The analysis shows that patients whose primary tumor is on the left of the colon (the side comprising the descending colon, sigmoid colon, and rectum) have a significantly longer survival than patients whose primary tumor is on the right side (where the cecum and ascending colon are located).
Lead author Alan P. Venook, a professor of medicine at the University of California-San Francisco (UCSF), explains that while previous studies have suggested tumor site can influence clinical outcomes in colorectal cancer, the effect they observed in their analysis is much bigger than they expected.
The study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, June 3-7, 2016.
ASCO President Julie M. Vose says this unexpected discovery "could answer some long-standing questions about why certain patients do better than others."
The data came from a clinical trial that compared bevacizumab and cetuximab in combination with chemotherapy as initial therapy for metastatic colorectal cancer.
Patients with left-sided primary tumors lived longer
In their main analysis, the researchers used data on 293 patients with right-sided primary tumors and 732 patients with left-sided primary tumors.
This analysis found that patients with left-sided primary tumors had a median overall survival of 33.3 months, compared with 19.4 months in patients with right-sided primary tumors.
Of the patients treated with cetuximab, those with left-sided primary tumors lived 36 months, while patients with right-sided primary tumors lived 16.7 months.
The analysis showed a similar pattern for patients treated with bevacizumab: 31.4 months overall survival for those with left-sided tumors and 24.2 months for those with right-sided tumors.
Another way to look at these results is from the point of view of tumor location first, then treatment. This shows if the tumor was on the right, patients receiving bevacizumab had a longer survival than patients receiving cetuximab (24.2 months and 16.7 months, respectively).
Conversely, patients with left-sided tumors treated with cetuximab lived 36 months, while those receiving bevacizumab lived 31.4 months.
As the clinical trial comparing the two drugs was under way, it was discovered that mutations in the KRAS gene is an important factor in the use of cetuximab.
When the researchers analyzed the data just for patients with KRAS mutations, they found a similar pattern to the previous results: patients with left-sided tumors lived longer compared with patients with right-sided tumors.
The researchers conclude that whether the primary tumor was on the left or the right likely influenced the effectiveness of the treatments the patients received in the trial.
They are now looking into the molecular biology mechanisms that might explain such differences.
"These findings will likely change the way we approach colorectal cancer treatment and research, even as we seek to more deeply understand the biology driving the difference in outcomes between right- and left-sided cancers."
Prof. Alan P. Venook
Colon cancer: Primary tumor location predicts survival
4/
5
Oleh
Unknown
2 comments
The past 4 years of my life has been years of torment right from when i was diagnosed with breast cancer (triple negative) stage IV. It was hard for me because i never in my life imagined i would have anything related to cancer. The first two years my oncologist gave me so much hope that i had to undergo chemo and radiation therapy twice and the lymph nodes were still there. It kept reoccurring and i was about to lose it all. I lost weight and i had high blood pressure due to steady thinking. I got the contact of Dr. Roland whom i was told treats cancer naturally with herbal medicine, i never believed but i was dying and to satisfy my curiosity i had to invite him over and he came with his medicine and began to treat me for a month. In three months time i didn't feel any symptoms and i decided to confirm and i went to my oncologist for a test and i tested negative to cancer. I never believed in herbal methods or treatments but now i do because it saved me. You too can contact him for more info on any form of cancer and also about his medicine and treatment process on (dr.rolandoscar@gmail.com) do not die in ignorance and never give up hope.
ReplyALL THANKS TO DR WILLIAMS WITH HIS HERBAL PORTION I WAS COMPLETELY CURED FROM BREAST CANCER.
ReplyI'm here again to appreciate. DR WILLIAMS God will always continue to bless you more abundantly, for the good works you done in my life, I will always keep on writing good and posting my testimonies about you on the Internet, I’m Jessica from Orlando, Florida. I was tested breast cancer positive, I saw a blog on how DR WILLIAMS cured people with his herbal portion, i did not believe in natural medicine but i just decided to give him a try, I contacted him,and explain my situation to him,few day later he sent me the herb, after taking doc Williams herbal medicine for few week i also got my healing with his herbal portion, i am so happy. If you have any type of cancer problem ,you can contact him on Drwilliams098675@gmail.com for advice and for his product,i hope this testimony also help some one out there .